

Silvy Lachance

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1380992/publications.pdf>

Version: 2024-02-01

42
papers

1,014
citations

687363

13
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

1882
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. <i>Bone Marrow Transplantation</i> , 2022, 57, 252-260.	2.4	6
2	UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 76.e1-76.e9.	1.2	11
3	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 157-161.	2.0	13
4	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
5	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1 safety and feasibility study. <i>Lancet Haematology</i> , 2020, 7, e134-e145.	4.6	138
6	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	5.8	53
7	Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. <i>European Journal of Haematology</i> , 2020, 105, 808-811.	2.2	3
8	UM171 Expansion Overcomes Shortcomings of Cord Blood Transplantation While Maintaining Benefits. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S294-S295.	2.0	0
9	Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S228-S229.	2.0	0
10	Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. <i>Clinical Transplantation</i> , 2020, 34, e14099.	1.6	4
11	UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections. <i>Blood</i> , 2020, 136, 36-37.	1.4	2
12	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. <i>Leukemia Research</i> , 2019, 79, 75-80.	0.8	8
13	Pharmacoeconomic Impact and Transplant Outcome Associated to Carmustine (BCNU) Substitution with Bendamustine (Be) in the Conditioning Regimen Prior to Autologous Stem Cell Transplantation for Lymphoma Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S131-S132.	2.0	0
14	Single UM171 Expanded Cord Blood Transplant is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S190-S191.	2.0	1
15	Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S173-S174.	2.0	0
16	Effectiveness of Continuous Infusion of Methylprednisolone for Prevention of Antithymocyte Globulin Infusion-Related Reactions in Preparative Regimens for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S331.	2.0	1
17	Bortezomib Consolidation after Frontline Auto-Allogeneic Transplant: Low Toxicity and Frequent Immunophenotypic Complete Responses in High-Risk or Young Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S250-S251.	2.0	0
18	Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival. <i>Blood</i> , 2018, 132, 4658-4658.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Impact of Omitting Prophylactic Antibiotics, to Preserve Gut Microbiota, on the Incidence of Bacteraemia during the Pre-Engraftment Period of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2094-2094.	1.4	0
20	Impact of High Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation on the Quality of Life of Elderly Patients Treated for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S225-S226.	2.0	0
21	Bortezomib Consolidation after Tandem Auto-Allogeneic Transplantation: High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Newly Diagnosed Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S269-S270.	2.0	0
22	The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. <i>Oncolmmunology</i> , 2017, 6, e1258506.	4.6	55
23	Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S353-S354.	2.0	0
24	Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S352-S353.	2.0	0
25	Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S37-S38.	2.0	1
26	Influence of Prophylactic Antibiotics Aiming at Gut Decontamination on Gastrointestinal Graft-Versus-Host Disease and Overall Survival Following Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4319-4319.	1.4	1
27	Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2562-2562.	1.4	1
28	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. <i>Blood Reviews</i> , 2014, 28, 249-261.	5.7	16
29	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. <i>Lancet, The</i> , 2014, 383, 436-448.	13.7	322
30	Nocardiosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Matched Case-Control Study of Risk Factors, Clinical Features and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S280.	2.0	5
31	Prompt Treatment of Respiratory Syncytial Virus with Inhaled Ribavirin and IVIG in High Risk Allogeneic Stem Cell Transplant Recipients Significantly Diminishes Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S258-S259.	2.0	0
32	Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 12-21.	2.0	45
33	Pneumatosis Coli Associated to Severe Intestinal Graft Versus Host Disease Following Hematopoietic Cell Transplantation: Risk Factors and Dismal Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S333.	2.0	1
34	Safety and Cost-Effectiveness of Outpatient Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 547-551.	2.0	60
35	Tandem Autologous Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 951-957.	2.0	23
36	High Incidence of Herpes Zoster in Nonmyeloablative Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1012-1017.	2.0	33

#	ARTICLE	IF	CITATIONS
37	Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1673-1678.	2.0	27
38	Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 919-929.	2.0	40
39	Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a) Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome.. <i>Blood</i> , 2008, 112, 1176-1176.	1.4	8
40	High Incidence of Invasive Aspergillosis Associated with Intestinal Graft-versus-Host Disease following Nonmyeloablative Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1192-1200.	2.0	66
41	Phase I Clinical Trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD.. <i>Blood</i> , 2007, 110, 2976-2976.	1.4	0
42	Phase I Clinical Study of Donor Lymphocyte Infusion Depleted of Alloreactive T Cells after Haplotype Mismatched Myeloablative Stem Cell Transplantation To Limit Infections and Malignant Relapse without Causing GVHD.. <i>Blood</i> , 2006, 108, 309-309.	1.4	6